Stock ARMP ARMATA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Market Closed - Nyse
Other stock markets
 16:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
2.77 USD +5.73% Intraday chart for Armata Pharmaceuticals, Inc. -2.02% -14.51%
05-07 Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-07 Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
MT
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
PU
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
MT
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
AQ
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
CI
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
AQ
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus
CI
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
AQ
Armata Pharmaceuticals, Inc. Announces CFO Changes
CI
Armata Pharmaceuticals, Inc. Announces Executive Changes
CI
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
AQ
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
AQ
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc
CI
Armata Pharmaceuticals, Inc. Announces Executive Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARMP Stock
  4. News Armata Pharmaceuticals, Inc.